Cancer Immunotherapy

The Cancer Immunotherapy research group investigates the molecular underpinnings of resistance to immune checkpoint inhibitor therapies. Their research centres on protein homeostasis in cancer cells, exploring how proteasome-mediated antigen processing and presentation can fail, enabling tumour immune evasion. Employing advanced tools, including CRISPR/Cas9 genome-wide screens, omics technologies, single-cell analyses, and in vitro and in vivo functional assays, they aim to identify the intrinsic mechanisms by which cancer cells resist immunotherapy and develop new strategies to overcome this resistance, ultimately achieving durable treatment responses.